

# Review on clinical features of Covid-19 Outbreak

NOOR AIN<sup>1</sup>

<sup>1</sup>The University of Faisalabad

July 28, 2020

## Abstract

The world has been under terror of another morbid viral pandemic which is a virus belongs to the corona virus family as SARS-COV2 (Severe acute respiratory syndrome-corona virus) related to previously existing SARS-COV (Severe acute respiratory syndrome) and MERS-COV (Middle East respiratory syndrome). It is considered to be zoonotic in origin as it is transmitted from animals to human. It presents crown like morphology with spike like protein which adheres to the surfaces of the body mainly in respiratory system. Mild symptoms like fever, dry cough, and body pain, loss of smell and taste, headache, shortness of breath appear on exposure to virus leading to major symptoms damaged lungs and drop in oxygen saturation. Pharmacological drug trials and various nutritional therapies are being used to prevent the symptoms of the infection. Researchers are developing proper vaccination to cure the infection.

## Introduction:

The establishment or occurrence of COVID-19 which is called as chronology of this infectious disease is as this. The foremost cases were known to be reported in December 2019. Commencing from 18th December all the way through 29th December 2019, 5 patients that were infected with this infectious disease were hospitalized in the midst of acute form of the respiratory agony condition furthermore one in those admitted patients died Park, M et al (2020). By January 3, 2020, 40 patients got admitted in the hospital and all of them were identified to be COVID-19 infected patients by the laboratory confirmation and just few of them had co-morbidities like cardiovascular, hypertension, cancer, asthma etc. it was considered that these patients might be infected due to the hospital acquired infections (NOSOCOMIAL). And it was presumed that this infection might be transmitted from one person to other person through various means like by air droplets, coughing, sneezing, by getting close to an infected person Bulut, C et al (2020). At beginning only patients with symptoms were checked clinically or by the hospitals to be infected but those with asymptomatic but having that infection were also a leading cause of its spread because they did not know that they are infected or not. In January 22, 2020, about 570 cases of this new infection were reported in different a province of China. Coronavirus is a type of viral disease that mainly affects the respiratory system of human. Preceding outbreaks of the coronaviruses (CoVs) embrace (SARS)-CoV the Severe acute respiratory syndrome along with (MERS)-CoV the Middle East respiratory syndrome that have been formerly considered to be the agents as those which have great threat to public health Lipsitch, M et al (2020). In December 2019, a huddle of the people infected with this viral infection got admitted in the hospitals having the preliminary verdict as of pneumonia with an indefinite etiology. The infected individuals were considered as they must be associated towards the seafood as well as damp animal market present in Wuhan, Hubei Province, China, Dong, Y et al (2020). On January 25, 2020, there were about 1975 cases were inveterate to be tainted by means of the COVID-19 within mainland of China and with the increase in mortality rate. After this to other confirmed reports suggested that about 5500 cases were present in China till the end of January, 2020. After this the cases were also reported from other countries too and the infected countries are as follows Thailand, Taiwan Malaysia, Sri Lanka, Vietnam, Nepal, Japan, Cambodia, Singapore, Italy, Republic of Korea, France, and Germany. Due to the emergence of the COVID-19 cases WHO, declared it as pandemic


in March 19, 2020 McMichael, T et al (2020). Now, the strategies regarding the treatment of infected patients are just supportive because there is no confirmed medicine or vaccine available for this infection. The other ways of reducing its chances to avoid social contact and the self-isolation at home can reduce the chances of its spread and also reduces the mortality rate Zhai, P et al (2020). The virus of COVID-19 has turned out to be the main pathogens of raising the respiratory syndrome outbreaks. There is a large family of the (+ssRNA) single stranded RNA virus with the intention of as it could be secluded in diverse species of animal Xie, J et al (2020). Due to its zoonotic origin it can also spread disease from animals to human when in close contact with each others like those of SARS-COV and MERS-COV. Amusingly, these last viruses have possibly originated as of bats furthermore subsequently stirring into the other mammalian species acting as host for these pathogens Van, W et al (2020).

### Symptoms:

The sign and symptoms of this infectious disease COVID-19 vary from mild to severe and at its peak severity where it mainly affects the lungs of affected person it may lead to death. The symptoms appear after the incubation period which is the time between exposure and the appearance of first symptom is about 5.2 days Fernandes and N (2020). The epoch as of the inception of the COVID-19 symptoms in the direction of death is from 6- 41 days by means of a norm about 14 days. The onset of symptoms of the disease and the death period is age dependent and immune status of the individual got infected. This period is shorter in the persons above 70 years of age than those under 70 years of age Klein, B et al (2020). It is significant to memorandum with the intention of the fact is that there must be some similarity in those of the symptoms flanked by the COVID-19 infection as well as former betacoronavirus like dry cough, dyspnea, fever, moreover as bilateral ground-glass opacities as in the CT scans of the chest Clay, J et al (2020). Conversely, COVID-19 appears to show various exceptional clinical experiences that embrace those of the affecting the lower airway as obvious by means of the symptoms of the upper respiratory tract like, sneezing, and rhinorrhoea along with the painful throat Fang, L et al (2020). Some most frequent symptoms which are at inception of the COVID-19 infirmity are those as fever, fatigue as well as cough Tian, S et al (2020), whereas supplementary symptoms consist of sputum production, haemoptysis, headache, diarrhea, as well as lymphopenia. Clinical experience exposed through the of the chest CT- scan offered as that the pneumonia, though, as there seems to be some unusual features like those of RNAemia Shereen, M et al (2020) acute cardiac injury, acute respiratory syndrome in addition to occurrence of the grand-glass opacities which is a leading cause of death. In a number of infected patients, the various peripheral ground-glass opacities were also seen in those of the sub pleural areas of the lungs as that probable initiated both localized as well as systemic type of immune response so as to cause amplified the inflammation Shi, Y et al (2020). Unfortunately, in some cases the treatment by means of interferon inhalation appears to have no clinical consequences moreover it appears to exacerbate the circumstances by moving ahead to the pulmonary opacities Bernheim, A et al (2020).

The results from the radiograph of chest also had shown the infiltrate in the upper lobes of lungs which may result in the occurrence of the dyspnea as well as hypoxemia Ng, M et al (2020). The patients suffering from the infection of COVID-19 also developed the GI (gastrointestinal) symptoms as those of diarrhea and abdominal pain etc. but these GI symptoms were less likely to be associated with those MERS-COV or SARS-COV patients Tian, S et al (2020). Consequently, it is imperative to check fecal as well as urine samples in the direction of to eliminate an impending substitute means of spread, particularly from the health care workers as well as patients Lei, S et al (2020). Consequently, progress of methods to recognize the diverse ways of spread like those of fecal along with urine samples are immediately defensible for the development of the ways to inhibit or minimize the transmission and it will also be helpful in the development of therapeutic strategies to control the disease Zhang, L et al (2020).

Some other symptoms as decrease in oxygen saturation and the coughing leads the patient to use oxygen or if in serious condition may be the use ventilator to stabilize the patient's condition and the symptoms may get worse if not treated properly or the person is already suffering from some other chronic disease as co-morbidity may lead to the chronic conditions Hu, Z et al (2020).



### Mode of transmission:

Genomic succession investigation of COVID-19 gives the evidence that about 88% similarities with 2 bat-derived (SARS) coronaviruses, signifying that the mammals are the for the most part have probable association flanked by COVID-19 with humans. Numerous reports have recommended that the transmission which is causative for spreading this infection is person-to-person transmission Mi, B et al (2020). This mode of transmission as Person-to-person transmission appears to be occurred mainly by means of the direct contact or may be all the way through the droplets spread by sneezing and coughing as of the infected person. But there is no transmission of the virus between mother and child either through placenta or via lactation in pregnant or lactating mothers. This is significant as the pregnant mothers are comparatively supplementary vulnerable to infection by means of pathogens of respiratory tract type of along with severe pneumonia Onder, G et al (2020). The infectious diseases can be transmitted from animal to the human and then further human to human transmission is also occurs. This transmission could be direct or indirect tin nature Yang, G et al (2020). But for SARS-COV2 we can explain this transmission is from animals to human (zoonotic) in nature due to the evaluation of the people working in animal market in Wuhan, China from where it actually spread Wu, Z et al (2020). The researchers are trying to find the reservoir host or the intermediate carrier which is actually the cause of spread to human. But, to date, we are unable to find the reservoirs other than mammals along with those of birds Jiang, F et al (2020).The binding of the receptor uttered through the cells of the host is the foremost step of this infection subsequent to union through cell membrane. It is consistent that the epithelial cells of the lungs are considered to be the target as of virus Huang, X et al (2020). Therefore, it has been reported that the person- to- person transmissions as of the SARS-CoV mainly appears to be occur through the binding of spikes of the virus with receptors of the cell as (ACE2)

angiotensin-converting enzyme 2 Jin, X et al (2020). Significantly, the succession of the receptor-binding COVID-19 domain related in the direction of the SARS-CoV. It also give the suggestion that entry and survival in the cell is via ACE2 receptors which facilitates its binding and also protect from harsh internal environment of body. And thus help in its survival in the body Mo, P et al (2020).

### **Etiology of covid-19:**

Common HCoV-OC43 (human CoVs), along with HCoV-HKU1 (betaCoVs of the A lineage, HCoV-NL63 along with) HCoV-229E (alphaCoVs) Wu, J et al (2020). These types of viruses can leads to the common colds as well as self-limiting type of upper respiratory infections in the individuals having immune system capable of fighting against them (immunocompetent) Hong, H et al (2020). In the individuals having weak immune system and could not compete the invading pathogens as immunocompromised in addition to the aged, the infections of the lower respiratory tract can arise Xiong, Y et al (2020).The members of this hefty family of the viruses can be a source of the respiratory, hepatic, enteric, along with those of the neurological disorders in diverse of animals species, together with those of camels, cats, cattle in addition to bats Shekerdeman, L et al (2020). Up to now, (HCoVs) human CoVs with seven different types are competent of infecting those of the humans have been recognized Qiao and J (2020). On the whole, the estimates recommend that those of two percent of the people are well with the carriers as of the CoV along with that these types of viruses are accountable in favor of having acute respiratory infections are 5% to 10% Henry, B et al (2020).Consequently, SARS-CoV-2 type of virus belongs to the betaCoVs group. It has shape as may be round or those of elliptic furthermore it is frequently pleomorphic (occurrence in various distinct forms) ,moreover, with the diameter about 60–140 nm. It is also sensitive to heat and UV (ultraviolet) radiations like other viruses from this group. Also the high temperature can also use to limit the replication of viruses Li, L et al (2020). At present, the temperature that inactivates SARS-CoV-2 ought to be well explained and its inactivation temperature is about 27° C.In contrast, it may oppose the cold temperature yet underneath 0°C Fang, L et al (2020). Additionally, these types of viruses can be efficiently made inactivated by the lipid types of solvents as, chlorine-containing disinfectant, ether (75%), ethanol, chloroform along with, peroxyacetic acid etc Chen, L et al (2020). Other types of the human CoVs as SARS-CoV, SARS-CoV-2, in addition to MERS-CoV (betaCoVs of the B along with C lineage, correspondingly) Surveillances and V (2020). They can be a source of the epidemics through inconsistent medical sternness it the features of respiratory along with extra-respiratory events. Pertaining to MERS-CoV and SARS-CoV, the transience rates are up to 11% and 36%, correspondingly Filatov, V et al (2020).In genetic stipulations, have confirmed that new HCoV genome, secluded as of a number of patient having the pneumonia which is atypical as subsequent to having a visit to Wuhan, they had about 89% nucleotide characteristics similar by means of those as that present in bat SARS-like-CoVZXC21 along with 82% as those of human SARS-CoV that’s why it is called SARS-CoV2 Zu, Z et al (2020). It has a RNA genome with 29891 nucleotides that encodes for those of 9 In genetic stipulations, have confirmed that new HCoV genome, secluded as of a number of patient having the pneumonia which is atypical as subsequent to having a visit to Wuhan, they had about 89% nucleotide characteristics similar by means of those as that present in bat SARS-like-CoVZXC21 along with 82% as those of human SARS-CoV that’s why it is called SARS-CoV2 Sun, P et al (2020). It has a RNA genome with 29891 nucleotides that encodes for those of 9860 amino acids. Possibly, a number of SARS-CoV-2 subsists. Even though the source of the SARS-CoV-2 is not completely tacit, but the genomic analysis put forward the evidence as the SARS-CoV-2 mainly evolved as of a strain present in bats Gao, J et al (2020). The probable amplifying mammalian host, transitional between those of bats as well as humans, unknown. As the alterations in novel strain may possibly encompass unswervingly triggered to the virulence in the humans Cascella, M et al (2020).

### **Pathogenesis:**

The core pathogenesis that describes COVID-19 infection as the virus that targets the respiratory system with rigorous pneumonia, joint as by means of the occurrence of ground-glass opacities, RNAemia, along with the cardiac injury that is cute in nature Shen, C et al (2020). Considerably higher levels of the cytokines along with chemokines in blood were eminent in the patients having COVID-19 infection and these included

as IL7, IL1RA, IL8, IL1- $\beta$ , IL9 and IL10 basic, GM-CSF, IP10, G-CSF, IFN $\gamma$ , MIP1 $\alpha$ , MCP1, PDGFB, MIP1 $\beta$ , TNF $\alpha$ , in addition to the VEGFA Dong, L et al (2020). The severe cases those who were in intensive care unit (ICU) also appeared with the elevated levels of the pro-inflammatory cytokines as those of the, IL7, IL2, IL10, IP10, G-CSF, MCP1, MIP1 $\alpha$ , as well as TNF $\alpha$  that are rational to endorse the severity of the disease Sanders, J et al (2020). The pathogenesis which explains the biological process or mechanism which leads to the disease state. The Patients tainted through COVID-19 showed to have the elevated numbers of the leukocyte as well as the anomalous findings of the respiratory tract, furthermore augmented levels as of the pro-inflammatory types of cytokines in the plasma Luo, P et al (2020). Some of the COVID-19 patients reports give the conclusion as present with fever with those of cough loutish breathing sounds in both the lungs, along with the temperature of body as about 39.0 °C. The sputum of the patient presented with the positive synchronized polymerase chain reaction consequences so as to confirm the infection of COVID-19 Ren, J et al (2020). The laboratory investigation showed the results with the appearance leucopenia by means of the leukocyte counts of about  $2.90 \times 10^9$  cells/L of which about seventy percent were the WBC type neutrophils. Furthermore, the elevated level of the C-reactive protein as with the value of about 16.16 mg/L which is exceeding the standard range of this C-reactive protein(0–10 mg/L). Also the elevated ESR (erythrocyte sedimentation rate) as well as the D-dimer was also pragmatic Wan, S et al (2020).

### **Treatment of COVID-19:**

At present there is no explicit antiviral or other types of treatment suggested for the COVID-19, furthermore, there is no vaccine presently existing. So, the way of treating the patient or the treatment option is symptomatic, as well as the oxygen (O<sub>2</sub>) therapy appears to be the first option for addressing respiratory mutilation Clerkin, K et al (2020). So the invasive mechanical ventilation (IMV) as well as NIV (Non-invasive ) mechanical type of ventilation might be indispensable in the cases of the respiratory collapse intractable to the O<sub>2</sub>( oxygen) therapy. Over again, the intensive care is required to pact by means of those of the intricate forms of this infectious disease Lim, J et al (2020). With reference to ARDS (Acute respiratory distress syndrome) treatment, gathering acquaintance on those of pathophysiology of damage to lungs, have steadily induced the clinicians to appraisal of the strategies required for managing the respiratory failure Cai, Q et al (2020). ARDS which is induced from COVID-19 (CARDS) is not a "usual" ARDS. This characteristic related to the disease is of elementary consequence as well as has possibly pessimistically exaggerated the remedial approach in the premature stages of the pandemic. Certainly, in spite of the start of pandemic, near the beginning IMV used to be considered as a better option for CARDS as in the pneumonia associated with COVID-19 and distinctive ARDS respiratory mechanics with the features as it abridged lung conformity (i.e., ability to stretch as well as expand lungs) cannot be establish Yoon, S et al (2020). In contrast, in CARDS, good pulmonary conformity can be established therefore, it is considered that CARDS can be treated well with IMV. The non-invasive ventilation (NIV) as well as high flow nasal oxygen therapy (HFNO), according to the experts' board, they consider that these are performed through the systems through high-quality border fitting that do not generate prevalent dispersal of the air that is exhaled, furthermore, its exploit can be considered at the squat peril of airborne spread Kupferschmidt, K et al (2020). The patients having the oxygen saturation (SpO<sub>2</sub>) as less than 93-94 percent or having the respiratory rate which is greater than 28-30 per minute and those facing the dyspnoea (difficult breathing) they must be given the oxygen as by the 40 percent Venturi mask Cunningham, C et al (2020). Following the 5- 10 minutes re-evaluation, stipulation the clinical along with instrumental depiction has enhanced then the patient may continues the management as well as May undergoes the reassessment during 6 hours. If the treatment shows no progress, or else new aggravation, the patient then undergoes the treatment which is non-invasive, in case it is not contraindicated Ye, Q et al (2020).

Since the process has a bigger hazard of the aerosolization, it ought to be used in those of the rooms having negative pressure. It is indicated when it is quite hard to maintain the oxygen saturation (SpO<sub>2</sub>) >92 percent or there is no improvement in dyspnoea via the standard oxygen therapy Bloch, E et al (2020). The setting of the procedure is as that 30 to 40 litter per minute and when the fraction of inhaled oxygen (FiO<sub>2</sub>) is about 50 to 60 percent then it is regulated according to the clinical response. The patient may be switched to the non-invasive ventilation (NIV) if there is no improvement in the symptom following one hour with

the oxygen flow > 50 liter per minute with the fraction of inhaled air as ( $FiO_2$ ) > 70 percent Paranjpe, I et al (2020). The HFNO can also be used as for the continuous positive air pressure (CPAP) breaks or in the critical patients. The procedure is contraindicated in the patients as those having hypercapnia (high level of carbon dioxide in blood) Mehra, M et al (2020).

This process is acting as it has a key role in the management of the COVID-19 related respiratory failure. It is done as the helmet is considered to reduce the hazards of aerosolization during the procedure. The process of NIV as if it is to be done with the face mask the use of the expiratory valve is incorporated as well as the tubes through the exhalation port ,furthermore, it then put an antimicrobial strain as on expiratory valve is suggested Touret, F et al (2020). The process of CPAP starts with those of 8 to 10 cm of water along with  $FiO_2$  as 60 percent. It is obligatory to not to craft numerous alterations in first 24 hours and following at least 4to6 hours if the patient is stable remove it as for about one hour and permit to take small quantity of fluids but it must be continued during night Guastalegname, M et al (2020). The process of Mechanical ventilation ought to be done with the lesser tidal volumes as 4- 6 ml/kg PBW (predicted body weight) as well as lesser inspiration pressures, attainment of the Pplat (plateau pressure) < 28 - 30 cm H<sub>2</sub>O. Positive end expiratory pressure (PEEP) has to be elevated as achievable to sustain the driving pressure as squat as feasible (< 14 cmH<sub>2</sub>O) Colson, P et al (2020). Furthermore, disconnections as of the ventilator have to be prohibited for avoiding the loss of PEEP as well as atelectasis. In conclusion, the exploit of the paralytics is not suggested except if  $PaO_2/FiO_2$  < 150 mmHg. The flat ventilation as for about > 12 hours per day, along with use of the traditional management of fluid approach in support of ARDS patients devoid of tissue hypo- perfusion must be emphasized Rothan, H et al (2020). Particular safety measures are obligatory all through the process of intubation. This process ought to be done by the professional operator who must uses the (PPE) personal protective equipment like N95 mask or FFP3, defensive goggles, disposable double socks, disposable gown along with gloves. If feasible, (RSI) rapid sequence intubation must be done Grein, J et al (2020). In this the Preoxygenation as giving 100 percent oxygen for about 5 minutes ought to be done through (CPAP) continuous positive airway pressure process. HME (Heat and moisture exchanger) have to be placed connecting the mask with circuit of fan or else may be flanked by the mask with the ventilation balloon Beigel, J et al (2020).

### **Drugs used symptomatically:**

There is no proper medicines available for COVID-19 treatment but the medicines given to the patient is just to treat the symptoms or these are given symptomatically also no vaccine is still present to avoid its spread or to provide immunity to those who don't have this infection Moore, J.B et al (2020). So, the symptomatic treatment which is given to the patients includes the drugs from different classes of drugs as; The drugs as from anti-malarial class and those also used in rheumatoid arthritis and systemic lupus erythmatosus (SLE) by decreasing the activity as of the immune system as 500mg of Chloroquine given after every 12 hours, along with 200mg of hydroxychloroquine which is given after every 12 hours were anticipated as having immunomodulatory role in therapy Rosa, S.G et al (2020). Even though no any antiviral specific treatments have been accepted, numerous approaches have been anticipated like lopinavir/ritonavir as given 400/100 mg orally after every 12 hours Lu, Q et al (2020).

Nonetheless, a current randomized, restricted trial as open-label has verified that there is no advantage through treatment with lopinavir/ritonavir when compared with the ordinary care. Preclinical studies have recommended that the treatment with remdesivir (GS5734) acting as an inhibitor of the RNA polymerase by means of an in vitro action adjacent to the several RNA viruses Yang, H et al (2020), counting Ebola might be effectual in favor of both prophylaxis as well as therapy of HCoV's ( human coronaviruses) infections. It was used in MERS-COV infection and alpha-interferon were also used Mizumoto, K et al (2020). Noteworthy, in a trial that was non-randomized revealed that the use of hydroxychloroquine was considerably related with the reduction in the viral load in anticipation of viral desertion; furthermore, this result was improved by the use of the antibiotics as macrolides (e.g. azithromycin). Both In vitro as well as in vivo trials, certainly Shim, E et al (2020), have revealed that macrolides antibiotics may possibly alleviate inflammation as well as amend the immune system of the individual. Specifically, these drugs possibly will stimulate the decrease in the

molecules as require for adhesion to the cell surface, plummeting the production of the proinflammatory cytokines, invigorating the process of phagocytosis through alveolar macrophages, as well as prohibiting the activation as well as recruitment of the neutrophils Kucharski, A.J et al (2020). Nevertheless, supplementary studies are required in favor of prescribing as well as recommending the exploit of azithromycin, unaccompanied or else coupled with supplementary drugs like hydroxychloroquine, exterior of any antibacterial groups Ludvigsson, J.F (2020). All over again, consideration ought to be remunerated by means of the associated use of the hydroxychloroquine along with azithromycin as alliance is able to escort to a elevated peril of the prolongation of the QT interval as well as arrhythmias. The use of Chloroquine can also encourage the prolongation of the QT interval Goyal, P et al (2020). For the reason that the patients of COVID-19 encompass an elevated prevalence of the venous thromboembolism along with anticoagulant therapy is linked through abridged ICU related death, it is recommended to the patients ought to be given the thromboprophylaxis therapy as well. Furthermore, in the case of identified thrombosis or thrombophilia, anticoagulation therapy as enoxaparin 1 mg/kg BD (twice daily) is recommended Jiang, F et al (2020). Another drug is use for the patients infected with COVID-19 and those who were in severe condition as Tocilizumab (monoclonal antibody and IL-6 blocker). A great number of the T lymphocytes as well as mononuclear type's macrophages are stimulated, and produce the cytokines for instance IL-6 (interleukin-6), which attach to receptor of IL-6 on target cells, and cause storm of cytokine as well as stern inflammatory reactions in lungs as well as the supplementary tissues along with the organs Zhang, L et al (2020). Tocilizumab, is( recombinant humanized anti-human IL-6 receptor monoclonal antibody), can attach to the IL-6 receptor by means of elevated affinity, consequently, and it will prevent the IL-6 itself as from fastening to its own receptors, depiction as it is unable of the immune harm to the target cells, as well as reducing the inflammatory reactions Wu, J et al (2020). Another drug from the steroid group of drugs e.g. Dexamethasone which is a artificial corticosteroid accepted by the FDA( food and drug administration) as an immunosuppressor which is broad-spectrum in nature as well as it is almost 30 times as active as well as having the duration of action which is 2-3 days is also longer compared to cortisone Tang, B et al (2020). This drug would perimeter the assembly as well as detrimental consequences of the cytokines; although, it will also restrain the defensive role of T cells along with obstruct the B cells as of producing the antibodies, potentially it would leads to the amplified plasma load of virus that will endure subsequent to the survival of the patient from SARS Pan, L et al (2020). Furthermore, dexamethasone would also obstruct the macrophages from reimbursement secondary, hospital acquired infections. Consequently, dexamethasone may be helpful in favor of the use of the drug for shorter duration in rigorous and intubated patients of the COVID-19, however, it might be absolute treacherous throughout resurgence as the virus will not only endure, although, the body will be prohibited as of producing defensive antibodies Han, C et al (2020). As a substitute, a pulse of the intravenous (IV) dexamethasone possibly will be followed by giving the triamcinolone which is nebulized which is 6 times as vigorous as cortisone to contemplate in the lungs merely. The corticosteroids might be recommended mutually with the natural flavonoid ( luteolin) since it has antiviral as well as anti-inflammatory effects, particularly its aptitude to restrain mast cells, which are the major cause of the cytokines present in the lungs Soetikno, R et al (2020). A further study exposed that the drug as ivermectin has shown its effectiveness in COVID-19 patients and it is an anti-parasitic which have broad spectrum drug. Ivermectin is FDA standard drug, recognized to encompass the broad-spectrum antiviral action against many viruses in the in vitro circumstances Mehta, P et al (2020). Current investigation on the ivermectin in opposition to the SARS-CoV-2 in those as in vitro trials exposed that it can restrain the replication of the virus. The distinct treatment with this drug was proficient to lessen the virus replication as up to the 5000-fold in the culture in 48h. Conversely, there is no supplementary diminution was appeared as with auxiliary add to the time period as when increased up to 72h Hollander, J.E et al (2020). Furthermore, there is no toxicity of the drug with the use for either 48 or 72 hours. the Mechanism through which ivermectin showed response in opposition to the CoV-19 virus is not recognized as well as it was supposed to be functioning likewise as it show effect on other types of viruses. It was recognized to restrain the nuclear importation of the viral as well as the host proteins Zheng, Y et al (2020). The Integrase protein as of the viruses along with the IMP (importin)  $\alpha/\beta$ 1 heterodimer was accountable for those as nuclear import (IN) which additionally promotes the infection. Because the majority of the RNA types of viruses are reliant on the IMP $\alpha/\beta$ 1 throughout the infection, Ivermectin show

effect on it along with inhibition of the importation by means of the amplified antiviral effect Akalin, E et al (2020).

### Other therapies:

The plasma which is taken from the recovered patients to use the antibodies present in it for those as seriously ill patients is known to be Convalescent plasma or the immunoglobulins. Furthermore, numerous investigations appeared as the subordinate transience as well as shorter hospital stay as in those patients given the convalescent plasma other than those that were not given as with the convalescent plasma. One probable clarification in favor of the effectiveness of the convalescent plasma therapy is as that the antibodies as from the convalescent plasma may repress the viraemia Velavan, T.P et al (2020). An in vivo study has also shown that the effects of the antibodies produced by this process were not merely restricted to the liberated clearance of the virus as well as they act by jamming the novel infections, although, it also incorporated with the hastening in the clearance of infected cell. The Viraemia as peaks in the 1st week of the occurring of infection in the majority of the viral illnesses Le, T.T et al (2020). The patient generally produces the prime immune rejoinder by 10–14 days, which is then subsequent to the virus removal. Consequently, hypothetically, it ought to be additionally effectual to the administration of the convalescent plasma at the early phase of the disease. Nevertheless, additional treatments may have a consequence as on the association between the convalescent plasma as well as the antibody level, counting as antiviral drugs, intravenous immunoglobulin as well as steroids Cao and X (2020).

Sr. no.	Drugs	Class of drug	Action
1	Azithromycin	Antibiotic	Act on the 50s ribosomal subunit of bacteria and inhibit prot
2	Chloroquine	Anti- malarial	Heme polymerase inhibitor
3	Tocilizumab	Anti-inflammatory	It has action of inhibition of the binding of ligand to the IL-6
4	Kaletra (ritonavir+lopinavir)	Anti-HIV	Protease inhibitor
5	Ivermectin	Anthelmintics	Cl <sup>-</sup> influx and hyperpolarization leads to muscle paralysis
6	Dexamethasone	Steroids	Immunosuppressive effect especially where there is cytokine s

### COVID-19 and co-morbidity:

The risk of getting this infection is increased in those who have an underlying disease like cancer, diabetes, hypertension, cardiovascular disorder, COPD (chronic obstructive pulmonary disease), renal disorder etc. and also those elderly patients may acquire this infection more quickly than others and it would also cause the increase fatality rate in those patients. The analysis recognized that the diseases like hypertension, COPD, diabetes, cardiovascular disease, in addition to the cerebrovascular disease as considerable threat factors for the patients of COVID-19 Poyiadji, N et al (2020). The comprehension of these factors is able to better describe the COVID-19 patients those are at greater risk of getting this infection in a severe form of infection with rapid multiplication of virus, furthermore, as a result it permit a supplementary beleaguered as well as explicit towards deaths and as a result increased fatality rate Remuzzi, A et al (2020).

### Prevention of spread of infection:

The measures as those required for the Prevention are the contemporary approach to frontier the extend of the cases. The Preventive measures are paying attention on the seclusion of the patients as well as vigilant control of the infection, together with the suitable actions that are adopted for the duration of the diagnosis as well as the stipulation of the clinical concern to a tainted patient. For example, the contact with the droplet, along with the airborne safety measures ought to be adopted throughout the sample assortment, as well as the sputum introduction ought to be prohibit Xia, Y et al (2020). The recommendations as from the authorized organizations are issued regarding the preventive measures, as to evade from get in touch with the individuals as those torment with the acute respiratory tract infections. It also includes as washing your hands recurrently, particularly subsequent to getting in touch with the tainted people or else

their surroundings Nishiura, H et al (2020). It also includes as avoiding the undefended contact to the wild animals or else farm. The persons having weak immune response (immunocompromised) ought to keep away from communal gatherings. The most of the significant approach intended for the people to embark on is to repeatedly clean their hands as well as the exploit the handy sanitizer in addition to evade contact as with their mouth as well as face subsequent to having interaction with a probably tainted surroundings. The people having symptoms as of the acute airway disease ought to be reserve from gathering, and wrap coughs or else sneezes by means of the throwaway tissues, clothes, moreover, clean their hands. Fortify, especially, in the emergency departments, the appliance of austere sanitation trials which are intended for the deterrence as well as to limit the infections Tian, S et al (2020).

### Concluding remarks:

Preceding studies give the results as that the genomes of CoVs exhibit an elevated extent of the agility in stipulations of the genes as well as their recombination. Moreover, the comparatively hefty genome of CoV causes the increased possibility on behalf of the mutations that are adaptive in nature, by means of it being the comparative ease of the proteins that have spikes to develop the multiple receptors that are cellular for the virus add-on along with entrance Yancy, C.W et al (2020). And these additional features are liable for being the cause of this distressing inclination of the CoVs on behalf of the host-species development. It may also subsist enviable to scrutinize farm animals as well as the pet cats for this infection of COVID-19, as the ACE2 receptors present in these animals are accountable for the COVID-19 virus fastening differs in just a few amino acids as of those present in human ACE2 receptors. Supervision may avert the virus production in another species of animal that have slam contact with the humans. Main acquaintance gaps concerning the appearance of COVID-19 linger exists; however, all-inclusive scientists are working as with unparalleled alacrity to inspect the virus, hastening to build up beleaguered therapeutic measures Lee, P.I et al (2020). Despite, a worldwide scrutiny complex concerning veterinarians along with animal biologists are immediately desired to scrutinize, along with probably to forecast, possible sources on behalf of the appearance of an additional exceedingly pathogenic CoV. The extensive actions to lessen the person-to-person spread of the COVID-19 are requisite to manage the existing outburst Lurie, N et al (2020). Exceptional consideration as well as efforts to shield and decrease transmission ought to be applied in vulnerable people as children, aged people as well as health care workers. The untimely mortality cases as of COVID-19 outburst occurred mainly in aged people, probably due to the frail immune system that allows the quicker development of the viral infection Rothan, H.A et al (2020). The changes in the COVID-19 illness ought to be monitored as taking into consideration as the impending routes of spread as well as subclinical types of infections, adding together to the adaptation, development, as well as the spread of the virus amongst humans as well as probable transitional animals along with reservoirs. So, there is need to develop the vaccine as soon as possible to eliminate this pandemic and to protect the rest of the world from this infectious disease Pfefferbaum, B et al (2020).

**Competing interest:** None, there are no competing interest.

### References:

1. Park, M., Cook, A. R., Lim, J. T., Sun, Y., & Dickens, B. L. (2020). A systematic review of COVID-19 epidemiology based on current evidence. *Journal of Clinical Medicine*, 9(4), 967. <https://doi.org/10.3390/jcm9040967>
2. Bulut, C. & Kato, Y. (2020). Epidemiology of COVID-19. *Turkish Journal of Medical Sciences*, 50(SI-1), 563-570. <https://doi.org/10.1007/s10916-020-01586-7>
3. Lipsitch, M., Swerdlow, D. L., & Finelli, L. (2020). Defining the epidemiology of Covid-19 studies needed. *New England Journal of Medicine*, 382(13), 1194-1196. DOI: 10.1056/NEJMp2002125
4. Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., & Tong, S. (2020). Epidemiology of COVID-19 among children in China. *Pediatrics*, 145(6), e20200702. DOI: <https://doi.org/10.1542/peds.2020-0702>
5. McMichael, T. M., Currie, D. W., Clark, S., Pogosjans, S., Kay, M., Schwartz, N. G., ... & Ferro, J. (2020). Epidemiology of Covid-19 in a long-term care facility in King County, Washington. *New England Journal of Medicine*, 382(21), 2005-2011. DOI: 10.1056/NEJMoa2005412

6. Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020). The epidemiology, diagnosis and treatment of COVID-19. *International Journal of Antimicrobial Agents*, 55(5), 105955. <https://doi.org/10.1016/j.ijantimicag.2020.105955>
7. Xie, J., Tong, Z., Guan, X., Du, B., Qiu, H., & Slutsky, A. S. (2020). Critical care crisis and some recommendations during the COVID-19 epidemic in China. *Intensive Care Medicine*, 46, 837–840. <https://doi.org/10.1007/s00134-020-05979-7>.
8. Van Lancker, W., & Parolin, Z. (2020). COVID-19, school closures, and child poverty: a social crisis in the making. *The Lancet Public Health*, 5(5), 243-244. [https://doi.org/10.1016/S2468-2667\(20\)30084-0](https://doi.org/10.1016/S2468-2667(20)30084-0)
9. Fernandes, N. (2020). Economic effects of coronavirus outbreak (COVID-19) on the world economy. Available at Social Science Research Network, <http://dx.doi.org/10.2139/ssrn.3557504>
10. Klein, B. C., & Busis, N. A. (2020). COVID-19 is catalyzing the adoption of teleneurology. *Neurology*, 94:903-904. <https://doi.org/10.1212/WNL.0000000000009494>
11. Clay, J. M., & Parker, M. O. (2020). Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? *The Lancet Public Health*, 5(5), 259. <https://doi.org/10.3390/ijerph17134677>
12. Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The Lancet. Respiratory Medicine*, 8(4), 21. [https://doi.org/10.1016/S2213-2600\(20\)30116-8](https://doi.org/10.1016/S2213-2600(20)30116-8)
13. Tian, S., Hu, N., Lou, J., Chen, K., Kang, X., Xiang, Z., & Chen, G. (2020). Characteristics of COVID-19 infection in Beijing. *Journal of Infection*, 80, 401-406. <https://doi.org/10.1016/j.jinf.2020.02.018>
14. Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *Journal of Advanced Research*, 24, 91-98. <https://doi.org/10.1016/j.jare.2020.03.005>
15. Shi, Y., Wang, Y., Shao, C., Huang, J., Gan, J., Huang, X., & Melino, G. (2020). COVID-19 infection: The Perspectives on Immune Responses, **27**, pages1451–1454. <https://doi.org/10.1038/s41418-020-0530-3>
16. Bernheim, A., Mei, X., Huang, M., Yang, Y., Fayad, Z. A., Zhang, N., ... & Li, S. (2020). Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. *Radiology*, 295, 685–691. <https://doi.org/10.1148/radiol.2020200463>
17. Ng, M. Y., Lee, E. Y., Yang, J., Yang, F., Li, X., Wang, H., & Hui, C. K. M. (2020). Imaging profile of the COVID-19 infection: radiologic findings and literature review. *Radiology: Cardiothoracic Imaging*, 2(1), e200034. [10.1109/RBME.2020.2990959](https://doi.org/10.1109/RBME.2020.2990959).
18. Tian, S., Hu, N., Lou, J., Chen, K., Kang, X., Xiang, Z., ... & Chen, G. (2020). Characteristics of COVID-19 infection in Beijing. *Journal of Infection*, 80(4), 401-406. <https://doi.org/10.1016/j.jinf.2020.02.018>.
19. Lei, S., Jiang, F., Su, W., Chen, C., Chen, J., Mei, W., ... & Xia, Z. Y. (2020). Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. *EClinicalMedicine*, 21, 100331. [doi.org/10.1016/j.eclinm.2020.100331](https://doi.org/10.1016/j.eclinm.2020.100331).
20. Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., ... & Peng, P. (2020). Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Annals of Oncology*, 31(7), 894-901. <https://doi.org/10.1016/j.annonc.2020.03.296>.
21. Hu, Z., Song, C., Xu, C., Jin, G., Chen, Y., Xu, X., ... & Wang, J. (2020). Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences*, 63(5), 706-711. <https://doi.org/10.1007/s11427-020-1661-4>.
22. Mi, B., Chen, L., Xiong, Y., Xue, H., Zhou, W., & Liu, G. (2020). Characteristics and early prognosis of COVID-19 infection in fracture patients. *The Journal of Bone and Joint Surgery*. 102(9), 750-758. [doi: 10.2106/JBJS.20.00390](https://doi.org/10.2106/JBJS.20.00390).
23. Onder, G., Rezza, G., & Brusaferro, S. (2020). Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *The Journal of American Medical Association*, 323(18), 1775-1776.
24. Yang, W., Cao, Q., Qin, L., Wang, X., Cheng, Z., Pan, A., ... & Yan, F. (2020). Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *Journal of Infection*, 80(4), 388-393.

- <https://doi.org/10.1016/j.jinf.2020.02.016>.
25. Wu, Z., & McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *The Journal of American Medical Association*, 323(13), 1239-1242.
  26. Jiang, F., Deng, L., Zhang, L., Cai, Y., Cheung, C. W., & Xia, Z. (2020). Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). *Journal of General Internal Medicine*, 35, 1545–1549. DOI: 10.1007/s11606-020-05762-w.
  27. Huang, X., Wei, F., Hu, L., Wen, L., & Chen, K. (2020). Epidemiology and clinical characteristics of COVID-19. *Archives of Iranian Medicine*, 23(4), 268-271. doi: 10.34172/aim.2020.09.
  28. Jin, X., Lian, J. S., Hu, J. H., Gao, J., Zheng, L., Zhang, Y. M., ... & Yu, G. D. (2020). Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*, 69(6), 1002-1009. <http://dx.doi.org/10.1136/gutjnl-2020-320926>.
  29. Mo, P., Xing, Y., Xiao, Y., Deng, L., Zhao, Q., Wang, H., ... & Luo, M. (2020). Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa270>.
  30. Wu, J., Liu, J., Zhao, X., Liu, C., Wang, W., Wang, D., ... & Cao, H. (2020). Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. *Clinical Infectious Diseases*, 10. <https://doi.org/10.1093/cid/ciaa199>.
  31. Hong, H., Wang, Y., Chung, H. T., & Chen, C. J. (2020). Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. *Pediatrics and Neonatology*, 61(2), 131-132. <https://doi.org/10.1016/j.pedneo.2020.03.001>.
  32. Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., ... & Wu, H. (2020). Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerging Microbes and Infections*, 9(1), 761-770. <https://doi.org/10.1080/22221751.2020.1747363>
  33. Shekerdemian, L. S., Mahmood, N. R., Wolfe, K. K., Riggs, B. J., Ross, C. E., McKiernan, C. A., & Priestley, M. A. (2020). Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. *JAMA Pediatrics*. DOI: <https://doi.org/10.1001/jamapediatrics.2020.1948>
  34. Qiao, J. (2020). What are the risks of COVID-19 infection in pregnant women?. *The Lancet*, 395(10226), 760-762. DOI: [https://doi.org/10.1016/S0140-6736\(20\)30365-2](https://doi.org/10.1016/S0140-6736(20)30365-2).
  35. Henry, B. M., & Lippi, G. (2020). Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *International Urology and Nephrology*, 52, 1193–1194 <https://doi.org/10.1007/s11255-020-02451-9>.
  36. Li, L. Q., Huang, T., Wang, Y. Q., Wang, Z. P., Liang, Y., Huang, T. B., & Wang, Y. (2020). COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *Journal of Medical Virology*, 92(6), 577-583. <https://doi.org/10.1002/jmv.25757>.
  37. Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. *The Lancet. Respiratory Medicine*, 8(4), e21. doi: 10.1016/S2213-2600(20)30116-8.
  38. Chen, L., Li, Q., Zheng, D., Jiang, H., Wei, Y., Zou, L., ... & Zhao, Y. (2020). Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. *New England Journal of Medicine*. 382, 100. DOI: 10.1056/NEJMc2009226.
  39. Surveillances, V. (2020). The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) China, 2020. *China CDC Weekly*, 2(8), 113-122.
  40. Filatov, A., Sharma, P., Hindi, F., & Espinosa, P. S. (2020). Neurological complications of coronavirus disease (COVID-19): Encephalopathy. *Cureus*, 12(3), e7352. doi: 10.7759/cureus.7352.
  41. Zu, Z. Y., Jiang, M. D., Xu, P. P., Chen, W., Ni, Q. Q., Lu, G. M., & Zhang, L. J. (2020). Coronavirus disease 2019 (COVID-19): a perspective from China. *Radiology*, 200490. <https://doi.org/10.1148/radiol.2020200490>.

42. Sun, P., Lu, X., Xu, C., Sun, W., & Pan, B. (2020). Understanding of COVID-19 based on current evidence. *Journal of medical virology*, 92(6), 548-551. <https://doi.org/10.1002/jmv.25722>.
43. Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Bioscience Trends*. 14(1), 72-73. <https://doi.org/10.5582/bst.2020.01047>
44. Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). Features, evaluation and treatment coronavirus (COVID-19). In *Statpearls* [internet]. StatPearls Publishing.
45. Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., ... & Wei, J. (2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *The Journal of American Medical Association*, 323(16), 1582-1589.
46. Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discoveries & Therapeutics*, 14(1), 58-60. <https://doi.org/10.5582/ddt.2020.01012>
47. Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *The Journal of American Medical Association*, 323(18), 1824-1836.
48. Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020). Tocilizumab treatment in COVID-19: A single center experience. *Journal of Medical Virology*, 92(7), 814-818. <https://doi.org/10.1002/jmv.25801>
49. Ren, J. L., Zhang, A. H., & Wang, X. J. (2020). Traditional Chinese medicine for COVID-19 treatment. *Pharmacological Research*, 155, 104743. doi: 10.1016/j.phrs.2020.104743.
50. Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., ... & Huang, X. (2020). Clinical features and treatment of COVID-19 patients in northeast Chongqing. *Journal of Medical Virology*. 92, 797-806. <https://doi.org/10.1002/jmv.25783>
51. Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., ... & Schwartz, A. (2020). COVID-19 and cardiovascular disease. *Circulation*, 141(20), 1648-1655. <https://doi.org/10.1161/CIRCULATIONAHA.120.046941>.
52. Lim, J., Jeon, S., Shin, H. Y., Kim, M. J., Seong, Y. M., Lee, W. J., ... & Park, S. J. (2020). Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. *Journal of Korean Medical Science*, 35(6), 79. <https://doi.org/10.3346/jkms.2020.35.e79>.
53. Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., ... & Shen, C. (2020). Experimental treatment with favipiravir for COVID-19: an open-label control study. *Engineering*. <https://doi.org/10.1016/j.eng.2020.03.007>.
54. c, S. H., Lee, K. H., Kim, J. Y., Lee, Y. K., Ko, H., Kim, K. H., ... & Kim, Y. H. (2020). Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea. *Korean journal of radiology*, 21(4), 494-500. <https://doi.org/10.3348/kjr.2020.0132>
55. Kupferschmidt, K., & Cohen, J. (2020). Race to find COVID-19 treatments accelerates. *American Association for the advancement of Science*. 367(6485), 1412-1413. DOI: 10.1126/science.367.6485.1412.
56. Cunningham, A. C., Goh, H. P., & Koh, D. (2020). Treatment of COVID-19: old tricks for new challenges. *Critical Care*. 24, 91.
57. Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of the Cytokine Storm in COVID-19. *Journal of Infection*, 80(6), 607-613. DOI:<https://doi.org/10.1016/j.jinf.2020.03.037>
58. Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., ... & Pekosz, A. (2020). Deployment of convalescent plasma for the prevention and treatment of COVID-19. *The Journal of Clinical Investigation*, 130(6), 2757-2765. <https://doi.org/10.1172/JCI138745>.
59. Paranjpe, I., Fuster, V., Lala, A., Russak, A. J., Glicksberg, B. S., Levin, M. A., ... & Zhao, S. (2020). Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. *Journal of the American College of Cardiology*, 76(1), 122-124. doi: 10.1016/j.jacc.2020.05.001.
60. Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)31180-6](https://doi.org/10.1016/S0140-6736(20)31180-6).

61. Touret, F., & de Lamballerie, X. (2020). Of chloroquine and COVID-19. *Antiviral Research*, 177, 104762. <https://doi.org/10.1016/j.antiviral.2020.104762>
62. Guastalegname, M., & Vallone, A. (2020). Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment?. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciaa321>.
63. Colson, P., Rolain, J. M., Lagier, J. C., Brouqui, P., & Raoult, D. (2020). Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. *Int Journal of Antimicrobial Agents*, 105932(10.1016).
64. Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity*, 109, 102433. <https://doi.org/10.1016/j.jaut.2020.102433>.
65. Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., ... & Nicastri, E. (2020). Compassionate use of remdesivir for patients with severe Covid-19. *New England Journal of Medicine*, 382(24), 2327-2336. DOI: 10.1056/NEJMoa2007016.
66. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., ... & Lopez de Castilla, D. (2020). Remdesivir for the treatment of Covid-19—preliminary report. *New England Journal of Medicine*. DOI: 10.1056/NEJMoa2007764.
67. Moore, J. B., & June, C. H. (2020). Cytokine release syndrome in severe COVID-19. *Science*, 368(6490), 473-474. DOI: 10.1126/science.abb8925.
68. Rosa, S. G. V., & Santos, W. C. (2020). Clinical trials on drug repositioning for COVID-19 treatment. *Pan American Journal of Public Health*, 44, e40. <https://doi.org/10.26633/RPSP.2020.40>.
69. Lu, Q., & Shi, Y. (2020). Coronavirus disease (COVID-19) and neonate: What neonatologist needs to know? *Journal of Medical Virology*, 92(6), 564-567. <https://doi.org/10.1002/jmv.25740>.
70. Yang, H., Wang, C., & Poon, L. C. (2020). Novel coronavirus infection and pregnancy. *Ultrasound in Obstetrics and Gynecology*, 55(4), 435-437. doi: 10.1002/uog.22006.
71. Mizumoto, K., Kagaya, K., & Chowell, G. (2020). Early epidemiological assessment of the transmission potential and virulence of coronavirus disease 2019 (COVID-19) in Wuhan City: China, January-February, 2020. medRxiv. doi: <https://doi.org/10.1101/2020.02.12.20022434>.
72. Shim, E., Tariq, A., Choi, W., Lee, Y., & Chowell, G. (2020). Transmission potential and severity of COVID-19 in South Korea. *International Journal of Infectious Diseases*. 93, 339-344. <https://doi.org/10.1016/j.ijid.2020.03.031>.
73. Kucharski, A. J., Russell, T. W., Diamond, C., Liu, Y., Edmunds, J., Funk, S., ... & Davies, N. (2020). Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *The Lancet Infectious Diseases*. 20(5), 553-558. [https://doi.org/10.1016/S1473-3099\(20\)30144-4](https://doi.org/10.1016/S1473-3099(20)30144-4).
74. Ludvigsson, J. F. (2020). Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatrica*, 109(6), 1088-1095. <https://doi.org/10.1111/apa.15270>
75. Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., ... & Hoffman, K. L. (2020). Clinical characteristics of Covid-19 in New York city. *New England Journal of Medicine*. 382, 2372-2374. DOI: 10.1056/NEJMc2010419.
76. Jiang, F., Deng, L., Zhang, L., Cai, Y., Cheung, C. W., & Xia, Z. (2020). Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). *Journal of General Internal Medicine*, 35, 1545-1549. doi: 10.3748/wjg.v26.i22.2987
77. Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., & Peng, P. (2020). Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Annals of Oncology*, 31, 894-901. <https://doi.org/10.1016/j.annonc.2020.03.296>
78. Wu, J., Liu, J., Zhao, X., Liu, C., Wang, W., Wang, D., & Cao, H. (2020). Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. *Clin Infect Dis*, 10.
79. Tang, B., Wang, X., Li, Q., Bragazzi, N. L., Tang, S., Xiao, Y., & Wu, J. (2020). Estimation of the transmission risk of the 2019-nCoV and its implication for public health interventions. *Journal of Clinical Medicine*, 9(2), 462. <https://doi.org/10.1016/j.idm.2020.02.001>
80. Pan, L., Mu, M., Yang, P., Sun, Y., Wang, R., Yan, J., & Jin, Y. (2020). Clinical charac-

- teristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *The American Journal of Gastroenterology*, 26(14): 1546–1553. doi: 10.3748/wjg.v26.i14.1546
81. Han, C., Duan, C., Zhang, S., Spiegel, B., Shi, H., Wang, W., & Hou, X. (2020). Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. *The American Journal of Gastroenterology*. 115, 916–923. doi: 10.14309/ajg.0000000000000664.
  82. Soetikno, R., Teoh, A. Y., Kaltenbach, T., Lau, J. Y., Asokkumar, R., Cabral-Prodigalidad, P., & Shergill, A. (2020). Considerations in performing endoscopy during the COVID-19 pandemic. *Gastrointestinal Endoscopy*. 92(1): 176–183. doi: 10.1016/j.gie.2020.03.3758.
  83. Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., & HLH Across Speciality Collaboration. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet (London, England)*, 395(10229), 1033–1034. doi: 10.1016/S0140-6736(20)30628-0.
  84. Hollander, J. E., & Carr, B. G. (2020). Virtually perfect? Telemedicine for COVID-19. *New England Journal of Medicine*, 382(18), 1679–1681. DOI: 10.1056/NEJMp2003539.
  85. Zheng, Y. Y., Ma, Y. T., Zhang, J. Y., & Xie, X. (2020). COVID-19 and the cardiovascular system. *Nature Reviews Cardiology*, 17(5), 259–260. <https://doi.org/10.1038/s41569-020-0360-5>.
  86. Akalin, E., Azzi, Y., Bartash, R., Seethamraju, H., Parides, M., Hemmige, V., ... & Liriano-Ward, L. (2020). Covid-19 and kidney transplantation. *New England Journal of Medicine*. 382:2475–2477. DOI: 10.1056/NEJMc2011117.
  87. Velavan, T. P., & Meyer, C. G. (2020). The COVID-19 epidemic. *Tropical Medicine & International Health*, 25(3), 278–280. doi: 10.1111/tmi.13383.
  88. Le, T. T., Andreadakis, Z., Kumar, A., Roman, R. G., Tollefsen, S., Saville, M., & Mayhew, S. (2020). The COVID-19 vaccine development landscape. *Nature Reviews Drug Discovery*, 19(5), 305–306. <https://doi.org/10.1038/d41573-020-00073-5>.
  89. Cao, X. (2020). COVID-19: immunopathology and its implications for therapy. *Nature Reviews Immunology*, 20(5), 269–270. DOI: <https://doi.org/10.1038/s41577-020-0308-3>.
  90. Poyiadji, N., Shahin, G., Noujaim, D., Stone, M., Patel, S., & Griffith, B. (2020). COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. *Radiology*, 201187. <https://doi.org/10.1148/radiol.2020201187>.
  91. Remuzzi, A., & Remuzzi, G. (2020). COVID-19 and Italy: what next?. *The Lancet*. 395(10231), 1225–1228. [https://doi.org/10.1016/S0140-6736\(20\)30627-9](https://doi.org/10.1016/S0140-6736(20)30627-9).
  92. Xia, Y., Jin, R., Zhao, J., Li, W., & Shen, H. (2020). Risk of COVID-19 for cancer patients. *Lancet Oncol*, 21(4), 180. [https://doi.org/10.1016/S1470-2045\(20\)30150-9](https://doi.org/10.1016/S1470-2045(20)30150-9).
  93. Nishiura, H., Oshitani, H., Kobayashi, T., Saito, T., Sunagawa, T., Matsui, T., ... & Suzuki, M. (2020). Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19). *medRxiv*. doi: <https://doi.org/10.1101/2020.02.28.20029272>.
  94. Tian, S., Hu, N., Lou, J., Chen, K., Kang, X., Xiang, Z., ... & Chen, G. (2020). Characteristics of COVID-19 infection in Beijing. *Journal of Infection*. 80(4), 401–406. <https://doi.org/10.1016/j.jinf.2020.02.018>
  95. Yancy, C. W. (2020). COVID-19 and African Americans. *Jama*.
  96. Lee, P. I., Hu, Y. L., Chen, P. Y., Huang, Y. C., & Hsueh, P. R. (2020). Are children less susceptible to COVID-19?. *Journal of Microbiology, Immunology, and Infection*. 53(3): 371–372. doi: 10.1016/j.jmii.2020.02.011.
  97. Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020). Developing Covid-19 vaccines at pandemic speed. *New England Journal of Medicine*, 382(21), 1969–1973. DOI: 10.1056/NEJMp2005630.
  98. Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity*, 109, 102433. <https://doi.org/10.1016/j.jaut.2020.102433>.
  99. Pfefferbaum, B., & North, C. S. (2020). Mental health and the Covid-19 pandemic. *New England Journal of Medicine*. DOI: 10.1056/NEJMp2008017.

## Hosted file

Table.docx available at <https://authorea.com/users/346729/articles/472619-review-on-clinical-features-of-covid-19-outbreak>

### Hosted file

Figures.docx available at <https://authorea.com/users/346729/articles/472619-review-on-clinical-features-of-covid-19-outbreak>